Gray MT, Cayrol R, May A, Skaugen JM, Hayek F, Lapointe S, Hawkins CE, Pearce TM, Pratt D, Wiredja D, Toland A, Marker DF. Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis. J Neuropathol Exp Neurol. 2026 Jul 01; 85(7):789-796.

Lozzi B, Gatesman TA, Dasgupta P, Sardar D, Ko Y, Mao C, Chen HC, Curry RN, Choi D, Mohila CA, Bondy ML, Rao G, Gallo M, Agnihotri S, Deneen B. Hp1bp3 loss links chromatin reorganization to metabolic vulnerability in glioma. Proc Natl Acad Sci U S A. 2026 Jun 16; 123(24):e2601061123.

Crowell C, Mankuzhy NP, Bennett J, Bandopadhayay P, Sturm D, Green AL, Gupta T, Chatterjee A, Epari S, Chinnaswamy G, Prasad M, Patel SH, MacNeil M, Vanan MI, Larouche V, Renzi S, Jones J, Perreault S, Mata-Mbemba D, Sangatsuda Y, Yoshimoto K, Lin E, Feddersen C, Cruz O, Pavon-Mengual M, Vizzini O, Zápotocký M, Popovacki A, Klawinski D, Hansford JR, Schlosser MP, Omene E, Alexander KL, Satgunaseelan L, Williams A, Yao K, Ronsley R, Cheng S, Ludlow L, Eisenstat D, Khuong-Quang DA, Tabouret E, André N, Matheson K, Chan A, Lim-Fat MJ, Lapointe S, Cayrol R, Coleman C, Juretic N, McThenia S, Khan S, Wright-Nadkarni M, Salloum R, Galvin RT, Sener U, Hawkins C, Imber BS, Karajannis MA, Jones DTW, Ligon KL, Jabado N, Erker C. Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study. Clin Cancer Res. 2026 Jun 01; 32(11):2243-2254.

Keane L, ?kandík M, Posada-Pérez M, Bose R, Desito J, van der Linde E, Engskog-Vlachos P, Ceccatelli S, Green AL, Joseph B. Microglia in diffuse midline glioma contribute to extracellular matrix remodelling and cancer cell invasion. Cell Death Dis. 2026 May 30; 17(1).

Krug B, Hu B, Chen H, Negrón-Lomas C, Chen X, El Mouatani A, Gretarsson KH, Ptack A, Deshmukh S, Kabir N, Jawhar W, Andrade AF, Jabbour E, Harutyunyan AS, Wang X, Taylor R, Lee JJY, Hulswit M, Faury D, Russo C, Xu X, Yang J, Baguette A, Dahl NA, Weil AG, Ellezam B, Dali R, Blanchette M, Wilson K, Garcia BA, Soni RK, Gallo M, Taylor MD, Kleinman CL, Majewski J, Jabado N, Lu C. H3K27me3 spreading organizes canonical PRC1 chromatin architecture to regulate developmental programs. Nat Genet. 2026 Jun; 58(6):1368-1382.

Erdem S, Haliloglu Y, Uslu IN, Houran M, Ulutabanca H, Vural A, Erturhan MB, Canatan H, Eken A. IDH1 Mutant Glioma Favors Group 3 Innate Lymphoid Cells and Is Resistant to Immune Checkpoint Expression. Inflamm Res. 2026 Apr 01; 75(1).

Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.

Lyons AT, Haizel-Cobbina J, Levine A, Bishay AE, Jew N, Li C, Patil P, Bennett J, Siddaway R, Yuditskiy R, Son A, Nakano Y, Patel PG, Ku M, Velázquez JE, Schniederjan MJ, Erker C, Cacciotti C, Santi M, Nelson EJ, Cheng S, Dunham C, Wilson B, Black K, van Landeghem FKH, Eisenstat DD, Guerreiro Stücklin AS, Weiser A, Larouche V, Giannakouros P, Fonseca A, Williamson L, Fernandes IL, Plant-Fox AS, Fleming AJ, Campbell S, Mushtaq N, Bukhari SI, Minhas K, Graham RT, Raskin S, Cvrlje FJ, Ludlow LE, Mulcahy Levy JM, Yamasaki K, Suzuki T, Ohka F, Arakawa Y, Ishihara T, Yamasaki F, Hansford JR, Luck A, Nasrallah MP, Toledano H, Masoud RM, Lassaletta A, Blasco-Santana L, Kilday JP, Talianski A, Davies HC, Johnston JM, Hale AT, Dirks PB, Rutka JT, Tabori U, Hawkins CE, Dewan MC. Disseminated pediatric low-grade glioma and hydrocephalus: a multinational consortium analysis of incidence and mortality. J Neurosurg Pediatr. 2025 Dec 12; 37(2):133-146.

Zannikou M, Duffy JT, Procissi D, Najem H, Levine RN, Thakur A, Hambardzumyan D, Lee-Chang C, Leoni L, Horbinski CM, Simberg D, Zhang B, Heimberger AB, Miska J, Balyasnikova IV. Bi-specific T cell-engaging antibody triggers protective immune memory and glioma microenvironment remodeling in immune-competent preclinical models. J Immunother Cancer. 2025 Oct 28; 13(10).

Singh K, Foster MW, Violette MJ, Corcoran AM, Hotchkiss KM, Railton CO, Blandford EE, Blethen KE, Thomas EL, McIntosh WC, Ashley DM, Desjardins A, Friedman HS, Johnson MO, Friedman A, Keir S, Buckley ED, Herndon JE, McLendon RE, Sampson JH, Calabrese E, López GY, Grant GA, Patel AP, Gregory SG, Li CY, Fecci PE, Khasraw M. A surgical window of opportunity trial evaluating the effect of the PCSK9 inhibitor evolocumab on tumoral MHC-I expression and CD8+ infiltration in glioma. Sci Rep. 2025 Oct 23; 15(1):37112.